Literature DB >> 26464668

Effect of rapamycin (RAPA) on the growth of lung cancer and its mechanism in mice with A549.

Linmei Wang1, Ruiling Wang2.   

Abstract

OBJECTIVE: To investigate the effects of rapamycin (RAPA) on the tumor growth of lung cancer in the mice bearing A549 and the mechanisms.
METHODS: 60 mice with A549 lung cancer models established were randomly divided into model group, low RAPA dose group and high RAPA dose group. The low dose group underwent intraperitoneal injection of 1.5 mg/kg RAPA, while the high dose group underwent intraperitoneal injection of 4.5 mg/kg RAPA, and the control group was given the same volume of PBS. 21 d after the administration, the changes of the tumor growth and survival rates of three groups were observed. RT-PCR and Western blot were utilized to analyze Caspase-3 mRNA and protein levels in the tumor tissues of the mice, and TUNEL staining method was used to analyze the cellular apoptosis of tumor tissues.
RESULTS: Compared with the model group, the low and high dose groups significantly inhibit tumor growth and have remarkably higher survival rates (P<0.05). The high dose group has obviously better effects on inhibiting tumors and a higher survival rate than low dose group (P<0.05). Compared with the model group, the low and high dose groups have significantly increased Caspase-3 mRNA and protein levels in tumor tissues (P<0.05), and higher cellular apoptosis rates in tumor tissues (P<0.05); Caspase-3 mRNA and protein levels and apoptosis rates of the mice's tumor tissues of high dose group are markedly higher than those of low dose group (P<0.05).
CONCLUSIONS: RAPA can significantly increase the expression of Caspase-3 in tumor tissues and promote the apoptosis of tumor tissue cells, and thus achieve good anti-tumor effects.

Entities:  

Keywords:  Caspase-3; Rapamycin; tumor growth

Mesh:

Substances:

Year:  2015        PMID: 26464668      PMCID: PMC4583900     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  17 in total

1.  Antitumor activity of acriflavine in lung adenocarcinoma cell line A549.

Authors:  Chia-Jen Lee; Chia-Herng Yue; Yu-Jie Lin; Yu-Yu Lin; Shao-Hsuan Kao; Jer-Yuh Liu; Yieng-How Chen
Journal:  Anticancer Res       Date:  2014-11       Impact factor: 2.480

Review 2.  Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).

Authors:  Massimo Di Maio; Filippo De Marinis; Fred R Hirsch; Cesare Gridelli
Journal:  Int J Oncol       Date:  2014-05-21       Impact factor: 5.650

3.  Stereotactic body radiotherapy for lung cancer: how much does it really cost?

Authors:  Yolande Lievens; Caroline Obyn; Anne-Sophie Mertens; Dries Van Halewyck; Frank Hulstaert
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

4.  Individualized altered fractionation as a more effective radiotherapy for non-small cell lung cancer.

Authors:  Yi-Jen Chen
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

Review 5.  Surgical management of advanced non-small cell lung cancer.

Authors:  Gonzalo Varela; Pascal Alexandre Thomas
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

6.  Correlation of tumor size as independent factor and disease stage with local recurrence of non-small cell lung carcinoma and its operability.

Authors:  Dejan Stojiljkovic; Nada Santrac; Tanja Stojiljkovic; Nebojsa Miletic; Dusica Gavrilovic
Journal:  J BUON       Date:  2015 Jan-Feb       Impact factor: 2.533

7.  Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

Authors:  Shigeru Kawabata; José R Mercado-Matos; M Christine Hollander; Danielle Donahue; Willie Wilson; Lucia Regales; Mohit Butaney; William Pao; Kwok-Kin Wong; Pasi A Jänne; Phillip A Dennis
Journal:  Cell Rep       Date:  2014-06-12       Impact factor: 9.423

Review 8.  mTOR inhibitors in the treatment of cancer.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Expert Opin Investig Drugs       Date:  2008-11       Impact factor: 6.206

9.  Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines.

Authors:  M Heuer; T Benkö; V R Cicinnati; G M Kaiser; G C Sotiropoulos; H A Baba; J W Treckmann; C E Broelsch; A Paul
Journal:  Transplant Proc       Date:  2009 Jan-Feb       Impact factor: 1.066

10.  Autophagic inhibitor attenuates rapamycin-induced inhibition of proliferation in cultured A549 lung cancer cells.

Authors:  R-Y Jiang; H-L Pei; W-D Gu; J Huang; Z-G Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

View more
  5 in total

Review 1.  Autophagy-related signaling pathways in non-small cell lung cancer.

Authors:  Jing Wang; Mei Gong; Xirong Fan; Dalu Huang; Jinshu Zhang; Cheng Huang
Journal:  Mol Cell Biochem       Date:  2021-11-10       Impact factor: 3.396

Review 2.  Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.

Authors:  Guangbo Liu; Fen Pei; Fengqing Yang; Lingxiao Li; Amit Dipak Amin; Songnian Liu; J Ross Buchan; William C Cho
Journal:  Int J Mol Sci       Date:  2017-02-10       Impact factor: 5.923

3.  Grain-Sized Moxibustion Heightens the AntiTumor Effect of Cyclophosphamide in Hepa1-6 Bearing Mice.

Authors:  Tao Zhu; Yanzhu Ma; Jianyun Wang; Xiaolin Chen; Jianhao Li; Liqiang Meng; Yuduo Hou; Yanting Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-08       Impact factor: 2.650

4.  Autophagy Alters Bladder Angiogenesis and Improves Bladder Hyperactivity in the Pathogenesis of Ketamine-Induced Cystitis in a Rat Model.

Authors:  Jian-He Lu; Yi-Hsuan Wu; Tai-Jui Juan; Hung-Yu Lin; Rong-Jyh Lin; Kuang-Shun Chueh; Yi-Chen Lee; Chao-Yuan Chang; Yung-Shun Juan
Journal:  Biology (Basel)       Date:  2021-05-30

5.  Neuroprotective effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-β 1-42 induced neurotoxicity and memory impairment.

Authors:  Paula Maria Quaglio Bellozi; Isabel Vieira de Assis Lima; Juliana Guimarães Dória; Érica Leandro Marciano Vieira; Alline Cristina Campos; Eduardo Candelario-Jalil; Helton José Reis; Antônio Lúcio Teixeira; Fabíola Mara Ribeiro; Antônio Carlos Pinheiro de Oliveira
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.